Would the LF–OPN complex be capable of blunting obesity, dyslipidemia, metabolic endotoxemia, and gut–liver axis pathogenesis (responsible for the development and progression of metabolic associated fatty liver disease)? This evidence concerns the gene SPP1 and metabolic syndrome.